+ Watch MYL
on My Watchlist
The Company develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients.
Mylan has seen and should continue to see rapidly expanding revenues due to the patent cliff and expanding prescription drug coverage. Add a robust share repurchase program and 11x forward earnings is a pittance to pay for a stock that has trounced the S&P over the past 5 years.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions